February 2010

Invivoscribe's subsidiary LabPMM™ announces release of NPM1  Mutation Assay & AML Mutation Panel

On February 1, 2010 we released our NPM1 Mutation Assay, which complements the FLT3 Mutation Assay currently in our test menu.
We offer both tests individually, as well as an AML Mutation Panel that tests both biomarkers. LabPMM™ is now the only reference laboratory outside Japan licensed to perform testing to determine FLT3 and NPM1 mutation status."